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Background: Total hip and knee arthroplasties are two of the most commonly performed procedures in
orthopedic surgery. Different blood-saving measures (BSMs) are used to reduce the often-needed allogenic blood
transfusions in these procedures. A recent large randomized controlled trial showed it is not cost effective to use
the BSMs of erythropoietin and perioperative autologous blood salvage in elective primary hip and knee
arthroplasties. Despite dissemination of these study results, medical professionals keep using these BSMs. To actually
change practice, an implementation strategy is needed that is based on a good understanding of target groups
and settings and the psychological constructs that predict behavior of medical professionals. However, detailed
insight into these issuses is lacking. Therefore, this study aims to explore which groups of professionals should be
targeted at which settings, as well as relevant barriers and facilitators that should be taken into acount in the
strategy to implement evidence-based, cost-effective blood transfusion management and to de-implement BSMs.
Methods: The study consists of three phases. First, a questionnaire survey among all Dutch orthopedic hospital
departments and independent treatment centers (n = 99) will be conducted to analyze current blood management
practice. Second, semistructured interviews will be held among 10 orthopedic surgeons and 10 anesthesiologists to
identify barriers and facilitators that are relevant for the uptake of cost-effective blood transfusion management.
Interview questions will be based on the Theoretical Domains Interview framework. The interviews will be followed
by a questionnaire survey among 800 medical professionals in orthopedics and anesthesiology (400 professionals
per discipline) in which the identified barriers and facilitators will be ranked by frequency and importance. Finally,
an implementation strategy will be developed based on the results from the previous phases, using principles of
intervention mapping and an expert panel.
Discussion: The developed strategy for cost-effective blood transfusion management by de-implementing BSMs is
likely to reduce costs for elective hip and knee arthroplasties. In addition, this study will lead to generalized
knowledge regarding relevant factors for the de-implementation of non-cost-effective interventions and insight in
the differences between implementation and de-implementation strategies.
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Total hip and knee arthroplasties are two of the most
commonly performed procedures in orthopedic surgery
[1,2]. It is expected that the number of these procedures
within the Netherlands will increase to more than 100,000
by the year 2030 [3]. During primary hip or knee arthro-
plasty, the calculated visible and invisible blood loss is
1,500 ml on average, followed by a drop of hemoglobin of
approximately 3 g/dl [4]. This leads to high rates of allo-
genic blood transfusions up to 69% depending on the
transfusion threshold [5]. Even though blood transfusions
may be necessary, they include the risk for infections and
noninfectious transfusion reactions [6].
Many studies on blood-saving measures (BSMs) have
therefore been performed, including erythropoietin
(EPO) and peri-operative autologous blood salvage
(intra-operative use of Cell Saver (CS) and a postopera-
tive drainage and reinfusion device (DR)). Reviews
showed that these studies had several limitations, such
as a retrospective design, small patient numbers and
poor methodological quality [5,7,8]. A multicenter ran-
domized controlled trial (RCT) with adequate power
(n = 2,442) was therefore performed recently to test the
cost effectiveness of using BSMs, including EPO, CS,
and DR, in elective primary hip and knee arthroplasties
[9]. It was shown that blood salvage (CS and DR)
resulted in neither decreased mean red blood cell (RBC)
use nor in a decrease in the proportion of transfused
patients and was more expensive due to the costs of the
devices used and a prolonged hospital stay. EPO showed
a significant decrease in the proportion of transfused
patients, but costs were considered too high. It was thus
concluded that these BSMs were not cost effective in
primary hip and knee arthroplasties [10].
Despite this evidence about BSMs not being cost ef-
fective, medical professionals keep using these BSMs in
daily practice. To decrease costs of care delivery to
patients undergoing a hip or knee arthroplasty, cost-
effective blood transfusion management needs to be
implemented. However, little is known about how to ef-
fectively de-implement common practices. To actually
change practice, a de-implementation strategy is needed
that is based on a good understanding of target groups
and settings and the barriers and facilitators that influ-
ence the behavior of medical professionals. [10,11] How-
ever, detailed insight into these factors is lacking.
Psychological theories are used in understanding and
predicting intentions and clinical behavior [12] and may
help to outline an effective strategy to de-implement
these non-cost-effective BSMs.
Objective
The Leiden Implementation Study of BlOod manage-
ment in hip and knee Arthroplasties (LISBOA) aims toexplore the target groups, settings, and relevant barriers
and facilitators that should be taken into account to de-
velop a strategy directed at all involved medical profes-
sionals (target group) and their organizations to
implement evidence-based, cost effective transfusion
management and to de-implement BSMs.
To reach the aim of this study, the following research
questions were formulated:
A. How often and in what settings are BSMs applied in
hip and knee arthroplasties?
B. Which barriers and facilitators influence the
implementation of cost-effective blood transfusion
management and de-implementation of non-cost-
effective BSMs among the target group, including
orthopedic surgeons and anesthesiologists?
C. What is a tailored implementation strategy for the
uptake of cost-effective blood transfusion
management given the results of the first two
research questions?
Methods
The study will be subdivided in three study phases to be
executed in one year:
A. analysis of current blood transfusion management
practice in elective primary hip and knee
arthroplasties (months 1 to 3),
B. analysis of barriers and facilitators relevant for the
implementation of cost-effective blood transfusion
management and de-implementation of non-cost-
effective BSMs (months 4 to 8),
C. development of an implementation strategy based
on the results of phases A and B (months 9 to 12).
The study design, study population, analysis, and out-
come measures are described per study phase.
Phase A: Analysis of current blood transfusion
management
Study design
To analyze current blood transfusion management prac-
tice in hip and knee arthroplasties, a survey among all
orthopedic departments of Dutch university, teaching,
and general hospitals and independent treatment centers
will be performed. A survey in the period 1995–1997
showed that EPO was used rarely in the Netherlands at
that time, in only 2% of all hospitals, and that CS was
used in 24% of hospitals [13]. A more recent survey in
2007 showed that approximately half of all Dutch ortho-
pedic departments applied EPO and/or autologous blood
salvage [14]. However, these surveys neither showed how
frequent these BSMs were applied within hospitals nor
in what type of setting (university, teaching, or general
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tion is needed to target the implementation strategy to
the appropriate professionals and departments.
The current survey will thus include questions about
the type and size of the department, the transfusion
protocol used, and the frequency of application of BSMs
in patients within the last 12 months. Furthermore,
questions will be included about the policy of preopera-
tive anticoagulant use. These last questions are added to
assess whether these protocols are related to BSM use
and should be taken into account in the implementation
strategy. The content of the survey will be developed to-
gether with an orthopedic surgeon, anesthesiologist, and
hematologist specialized in blood transfusions. Remin-
ders to nonresponders will be sent after two weeks and
again by telephone after four weeks.
Study population
All heads of orthopedic departments of Dutch university,
teaching, and general hospitals and independent treat-
ment centers (n = 99) will be approached to participate
in the survey. In case of nonresponse, a different ortho-
pedic surgeon within the same department will be
approached.
Analysis
Descriptive statistics will be used to describe current
blood management practice. Independent t tests or
Mann Whitney U tests for continuous variables and
Chi-Square tests or Fisher’s exact tests for proportions
are used to analyze differences in frequency of use be-
tween the different settings, department sizes, or other
conditions.
Outcome measures
The main outcome measures are the percentage of
orthopedic departments applying BSMs per size and
type of setting of the orthopedic department and the fre-
quency of BSM use within a department. These results
are used in phase C to address the implementation strat-
egy to the appropriate (groups of) orthopedic depart-
ments. A secondary outcome measure is the number of
days anticoagulants are stopped preoperatively. This is
used to analyze whether this is associated with BSM use
and should be taken into account in the implementation
strategy.
Phase B: Analysis of barriers and facilitators for
implementation of cost-effective blood
transfusion management
Study design
Two steps will be taken to identify barriers and facilita-
tors associated with the implementation of cost-effective
blood transfusion management. First, semistructuredinterviews will be performed to explore all relevant bar-
riers and facilitators for the uptake of cost-effective blood
transfusion management. The interview questions will be
based on the Theoretical Domains Interview (TDI) frame-
work [15], complemented by the framework of Cabana,
who subdivided largely similar constructs in three
“sequences of behavior change” to give a good overview
of the used constructs [16]. The TDI framework includes
12 theoretical construct domains derived from 33 health
psychology theories (covering 128 theoretical constructs)
that help explain clinicians’ behavior [15,17].
Second, a survey will be held among a random sample
of 400 Dutch orthopedic surgeons and 400 anesthesiolo-
gists to rank the barriers and facilitators identified in the
interviews both on frequency and importance. The sur-
vey will include questions in which these barriers and
facilitators of the identified theoretical domains can be
related to specific clinical behavior.
Study population
Orthopedic surgeons and anesthesiologists are key stake-
holders in deciding to use allogenic blood transfusions
only or BSMs in patients that undergo hip and knee
arthroplasty. Based on the analysis of current practice
(phase A of this study), we will select a sample of depart-
ments that frequently apply BSMs to identify barriers, as
well as departments with rare use of BSMs to identify
facilitators. In this selection, the setting is taken into ac-
count (university, teaching, or general hospital or inde-
pendent treatment center). In addition, departments
with alternative answers (e.g., the use of a different trans-
fusion protocol) will be selected for interviews. In total,
ten orthopedic surgeons and ten anesthesiologists will
be interviewed to identify barriers and facilitators rele-
vant for the uptake of a cost-effective blood transfusion
policy and their motivations to apply BSMs. Data satur-
ation for the interviews is defined as three consecutive
interviews without new themes emerging. If there is no
data saturation after 10 interviews per specialism, add-
itional interviews will be conducted. [18] The total num-
ber of interviews will thus be determined by the number
it takes to reach data saturation.
The interviews with orthopedic surgeons and anesthe-
siologists may reveal that other groups of stakeholders
have an important role in deciding to use BSMs. In that
case, additional interviews will be held with those stake-
holders to elicit their views about relevant barriers and
facilitators associated with the uptake of cost-effective
transfusion management.
For the survey, a random sample (n = 400) of all Dutch
orthopedic surgeons listed in the registry of the Dutch
Orthopedic Association (NOV) (n = 595) and a random
sample (n = 400) of anesthesiologists listed in the registry
of the Netherlands Society of Anesthesiologists (NVA)
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the survey.
Analysis
The interviews will be audiotaped and transcribed in full
for analysis. The interview transcripts will be analyzed
by two researchers using the TDI framework as a base
[15]. Important theoretical domains and the barriers and
facilitators within these domains will be coded. This
qualitative analysis will be executed using the software
package ATLAS.ti (ATLAS.ti Scientific Software Devel-
opment GmBH, Berlin, Germany).
The subsequent survey data will allow us to rank the
importance of barriers and facilitators and their relation-
ships with behavioral intention. These relationships will
be assessed using regression analysis.
Outcome measures
The most important barriers and facilitators relevant for
the uptake of cost-effective blood transfusion manage-
ment by medical professionals will be the outcome mea-
sures from this phase.
Phase C: Development of an effective
implementation strategy for cost-effective blood
management
Study design
The results from the previous phases will be used to
develop a tailored implementation strategy for cost-
effective blood transfusion management for elective pri-
mary hip and knee arthroplasties. The results from
phase A will show to which type of departments the
strategy should be aimed. Phase B results will show the
most important barriers and facilitators that should be
taken into account in the development of the strategy.
From the literature, it is known that, in general, multi-
faceted strategies are more effective than single strategies
[19,20]. Assuming this, and our expectation that several
barriers on different theoretical domains will be found, it
is very likely that the implementation strategy to be devel-
oped will include several components directed at different
levels (i.e., professional and organizational context). Fur-
thermore, it is expected that the strategy components will
include educational outreach or interactive educational
strategy since these are known to be effective [20,21].
In the development process, we will use a method
based on the intervention mapping approach of Bar-
tholomew et al. [22]. This method begins with the cre-
ation of matrices in which the performance objectives
are set against the top 10 ranking of factors that hinder
or facilitate the implementation of a cost-effective trans-
fusion policy. Subsequently, a brainstorming session will
be held about the strategy components needed to
achieve the performance objective, in the presence orabsence of the hindering or facilitating factor mentioned
in the matrix. The cells of the matrices will then grad-
ually be filled with implementation strategy components
[23]. Next, the formulated strategy components will be
translated into practical strategies at each level (e.g., pro-
fessional and organizational).
After the implementation strategy is developed, an ex-
pert meeting will be held with a panel of key opinion
leaders in orthopedic surgery and anesthesiology, dele-
gates of blood transfusion committees, and implementa-
tion experts (n = 10 to n = 20) to discuss the strategy’s
feasibility and to refine the developed implementation
strategy. Their opinion about the strategy and their
intention to use the strategy will be taken into account.
Analysis
The expert meeting will be audiotaped and transcribed.
The panel members will receive a summary of the for-
mulated implementation strategy and will be asked
whether this summary is consistent with the conclusions
reached in the meeting.
Outcome measures
The outcome from this phase will be a tailored imple-
mentation strategy likely to be effective for imple-
menting cost effective blood transfusion management
and de-implementing BSMs in elective primary hip and
knee athroplasties.
Ethical approval
The study protocol has been presented to the Medical
Ethical Committee of the Leiden University Medical
Center. They declared ethical approval was not required
under Dutch national law. (CME 11/104)
Discussion
The goal of this study is to develop an implementation
strategy for cost-effective blood transfusion management
in elective hip and knee arthroplasties in which BSMs
are de-implemented. This study is the next step follow-
ing a RCT on EPO and blood salvage as transfusion
alternatives in orthopedic surgery using a restrictive
transfusion policy that showed that use of these BSMs is
not cost effective [9]. Given the number of hip and knee
arthroplasties performed annually in the Netherlands
and worldwide, and the accompanied blood loss and
transfusion risks, implementing a cost-effective blood
transfusion management may reduce costs.
Several studies have been performed to develop and
test implementation strategies, including identification
of barriers that prevent implementation [10,16,19]. They
all conclude that a prior inventory of barriers to develop
a tailored implementation strategy is useful and can con-
firm whether barriers differ in different settings. Prior
Voorn et al. Implementation Science 2012, 7:58 Page 5 of 6
http://www.implementationscience.com/content/7/1/58inventory thereby reduces the number of costly trials
evaluating different implementation strategies. [11,24,25]
The present study, however, focuses on de-implementation
of BSMs known to be cost ineffective. Little is known
about barriers and facilitators for de-implementation and
whether these are similar to barriers and facilitators for
implementation. The knowledge obtained by the present
study may thus be further generalized to other prac-
tices that need to be de-implemented and contributes
to general knowledge regarding differences between
de-implementation and implementation strategies.
Strengths and limitations
Possible limitations of the study are biased results due to
response bias in the phase A survey [26]. Nonresponse
may cause an under- or overestimation of BSM use. The
selection for the interviews in phase B is based on the
results of phase A, so if non-responders have different
intentions or experience different barriers and facilita-
tors for the uptake of cost-effective blood transfusion
management, this may influence the resulting barriers
and facilitators.
We will try to overcome this by sending reminders by
email and telephone, but this will not completely prevent
response bias. In addition, response bias may also occur
in the phase B survey if nonresponders to this survey
rank the selected barriers and facilitators in a different
order; this may influence the likelihood of barriers and
facilitators being included in the implementation strategy.
Again, reminders will be sent to keep bias to a minimum,
and we will compare respondents and nonrespondents on
demographic variables (e.g., type of hospital) to estimate
how likely it is that bias may be introduced.
A strength of this study is that it is one of the first
studies to identify barriers and facilitators relevant for
de-implementation. The study results will thus lead to
generalized knowledge regarding factors that are import-
ant for the de-implementation of non-cost-effective
interventions and how these differ from relevant factors
for implementation.
Future work
The developed implementation strategy should be tested
for effectiveness, feasibility, and costs within orthopedic
practice in the Netherlands in a future study. As the
current implementation strategy will be aimed at de-
implementation of the use of EPO, CS, and DR, further
research is needed to evaluate the cost effectiveness of
other BSMs in hip and knee arthroplasties. Cost effective
blood transfusion management implemented in this way
is likely to improve efficiency of care.
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